Data verified as of June 19, 2026, sourced from the NSE Nifty Pharma Index free-float market capitalisation weightage. Rankings shift as share prices move — this page is maintained and re-checked against live exchange data, not a one-time snapshot.
Twenty-three years in pharma QC, QA and regulatory affairs teaches you one thing fast: a “top pharma companies” list is only as good as the day it was pulled. Market cap in this sector moves weekly — a single US FDA approval, a semaglutide licensing deal, or a quarterly earnings miss can shuffle three positions in a ranking overnight. Dr. Reddy’s, for instance, posted an 86% year-on-year drop in net profit for Q4 FY26 on a stock shelf write-down, and that alone was enough to push it out of the top five by weightage. If a list you’re reading doesn’t tell you the date the data was pulled, treat the ranking with caution.
This page ranks India’s listed pharma majors by their free-float weightage within the NSE Nifty Pharma Index — the same market-cap-based methodology NSE itself uses to construct the index — rather than copying an older ranking forward. We also flag where index weighting rules (which cap any single constituent’s influence) mean the raw market-cap order could read slightly differently from the index weight order.
Top 10 Pharma Companies in India by Market Cap (June 2026)
| Rank | Company | Nifty Pharma Weight* | HQ | Primary Focus |
|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries | 23.01% | Mumbai | Specialty generics, dermatology, oncology |
| 2 | Divi’s Laboratories | 9.34% | Hyderabad | APIs & intermediates (CRAMS) |
| 3 | Torrent Pharmaceuticals | 7.82% | Ahmedabad | Chronic/branded generics (cardiac, CNS) |
| 4 | Cipla | 5.71% | Mumbai | Respiratory, ARV, complex generics |
| 5 | Lupin | 5.61% | Mumbai | Inhalation, anti-TB APIs, biosimilars |
| 6 | Zydus Lifesciences | 5.58% | Ahmedabad | Generics, vaccines, US formulations |
| 7 | Dr. Reddy’s Laboratories | 5.54% | Hyderabad | Global generics, biosimilars, vaccines |
| 8 | Mankind Pharma | 5.21% | Delhi | Domestic branded formulations, consumer health |
| 9 | Biocon | 3.52% | Bengaluru | Biosimilars, insulins, oncology biologics |
| 10 | Alkem Laboratories | 3.36% | Mumbai | Anti-infectives, gastroenterology, generics |
Weight = free-float market capitalisation share within the NSE Nifty Pharma Index as of June 19, 2026. Index methodology applies concentration caps, so extremely large constituents can show a marginally compressed weight relative to unadjusted market cap. Source: NSE Indices.
Sortable version with net sales, WHO-GMP/USFDA status and export markets is below — click any column header to reorder.
Top 10 Pharma Companies in India — Market Cap Comparison
Data verified as of March 2026 · Source: NSE/BSE listed market capitalisation, company annual reports
| Rank | Company | Headquarters | Primary Focus | Regulatory Approvals | Export Reach |
|---|
What Changed Since the Last Ranking Refresh
Two shifts are worth calling out because they explain why this order differs from most other “top 10” lists still circulating:
- Biocon has entered the top 10, displacing Aurobindo Pharma. Biocon’s biosimilars business grew revenue 16% and EBITDA 40% in FY26 on a like-for-like basis, and its stock is up close to 30% year-on-year — momentum tied to India’s Budget 2026-27 Biopharma Shakti programme and Biocon’s position among the top five global biosimilars players.
- Dr. Reddy’s and Cipla have both slipped from their historical #2–#4 positions. Dr. Reddy’s took a sharp earnings hit in Q4 FY26 tied to a stock-shelf adjustment and pricing pressure in key export markets, while Torrent and Lupin gained ground on stronger chronic-therapy and semaglutide-licensing momentum respectively.
If you’re benchmarking plant capacity, an M&A target, or a franchise partner against “the top 10,” which specific list you’re reading — and how recently it was refreshed — matters more than most sites let on.
What This Ranking Means for Plant Capacity and Partner Selection
A market-cap ranking is a proxy for scale, not for manufacturing quality — but the two are not unrelated, and this is where our angle differs from a pure finance page. Companies holding the top spots by market cap are, almost without exception, running multi-site WHO-GMP and USFDA-inspected facilities with capacity in the tens of thousands of tonnes of formulation output annually. That scale creates two things worth understanding if you’re evaluating a plant purchase, a third-party manufacturing partner, or a franchise tie-up:
- Capacity headroom gets absorbed by the majors first. When a top-10 company like Torrent or Zydus signs a licensing deal (both recently entered the semaglutide market — Torrent via Zydus, Lupin via the same route), contract manufacturing demand for peptide and injectable capacity tightens across the mid-market almost immediately. Smaller and mid-cap plants often see indirect demand spillover within two to three quarters.
- WHO-GMP and USFDA approval status at these companies sets the de facto compliance bar. If you’re benchmarking your own facility or a plant you’re evaluating against “industry standard,” the top 10’s approval footprints (USFDA, UK MHRA, WHO-GMP, TGA) are the realistic reference point regulators and buyers will compare you to — not the minimum CDSCO Schedule M requirement.
If you’re assessing a pharma plant for sale or considering a third-party manufacturing tie-up, the capacity and compliance trends set by these ten companies are the context worth checking first — our CDSCO Schedule M compliance dashboard tracks where the regulatory bar is currently sitting.
Profiles of the Top 10 Pharma Companies in India (June 2026)
1. Sun Pharmaceutical Industries — India’s Largest by a Wide Margin
Sun Pharma holds roughly 23% of the Nifty Pharma Index’s free-float weight — more than double the next-largest constituent. It commands an 8.4% domestic prescription market share as of March 2026 alongside its market-cap lead, driven by specialty dermatology and oncology drugs (Ilumya, Levulan among them) sold across 100+ countries. Around 70% of revenue comes from international markets, with the Taro merger (completed 2024) and the Checkpoint Therapeutics acquisition (adding UNLOXCYT, an FDA-approved anti-PD-L1 therapy) both consolidating its specialty and dermatology pipeline.
2. Divi’s Laboratories — India’s API Powerhouse
Divi’s is structurally different from every other name on this list: it doesn’t sell branded formulations, it manufactures active pharmaceutical ingredients and intermediates for other companies’ medicines — a model that commands premium margins. Q3 FY26 revenue grew 25% to ₹2,319 crore, with profit after tax up 65% to ₹589 crore. Its Kakinada Unit-III greenfield site is progressively adding capacity, and its Hyderabad and Visakhapatnam facilities hold USFDA and UK MHRA approvals alongside other major regulatory sign-offs.
3. Torrent Pharmaceuticals — Chronic Care, Acquisition-Led Growth
Torrent has built a durable branded-generics franchise in cardiovascular, CNS, gastrointestinal and women’s health across 50+ countries, and holds the distinction of being the first Indian company to reach the highest prescription market share in both Germany and Brazil. A string of acquisitions — Elder Pharma’s Indian brands, Unichem’s domestic portfolio, and Pfizer’s German subsidiary — gave it multi-geography scale. In 2026 it entered the semaglutide market in India via a licensing deal with Zydus, and the stock delivered a 39% one-year return.
4. Cipla — Respiratory Leadership, Access-First Model
Nine decades in, Cipla still anchors its business around respiratory medicine — inhalers and nebulisers remain its flagship franchise — while manufacturing 1,500+ products across 65+ therapeutic categories in 80+ countries. It’s the third-largest player in India’s private prescription market, and its Global Access business continues to prioritise HIV, TB and other high-burden disease treatment in low- and middle-income countries alongside its complex respiratory generics push in regulated markets.
5. Lupin — Global Generics, Semaglutide Entry, Digital Health
Lupin operates across 100+ countries through 15 manufacturing facilities and 7 R&D centres, and holds the position of the world’s largest supplier of anti-TB APIs. It entered the semaglutide market in 2026 through a licensing deal with Zydus for reusable pen technology, and is one of the few Indian majors building patient-facing digital health tools — its Lyfe app supports cardiac rehabilitation. The stock hit new 52-week highs in May 2026.
6. Zydus Lifesciences — Vaccines, Biologics, Licensing Hub
Formerly Cadila Healthcare, Zydus employs 26,000+ people across plants in six Indian states and has become the licensing counterparty for both Torrent’s and Lupin’s semaglutide entries — its pipeline spans biologics, biosimilars, vaccines and complex generics including monoclonal antibodies and peptides. In 2026 it received final USFDA approval for generic Eltrombopag tablets and was among the first companies approved for semaglutide in both diabetes and obesity indications in India.
7. Dr. Reddy’s Laboratories — Diversified Generics Under Near-Term Pressure
Dr. Reddy’s operates across 76 countries with EcoVadis Gold Medal sustainability recognition, and filed 12 first-to-file ANDAs in the US against FY2026 patent expiries while securing early Indian approval for a semaglutide generic. That said, its Q4 FY26 results were rough: net profit dropped 86.2% year-on-year to ₹220.1 crore on an 11.6% revenue decline, driven by a stock-shelf adjustment and price erosion in key export markets — the primary reason it has slipped several places in this ranking versus earlier in the year.
8. Mankind Pharma — Domestic Scale, Rising R&D Ambition
Mankind combines one of India’s largest prescription portfolios with widely recognised consumer brands (Manforce, Prega News, Unwanted-72) across antibiotics, gastrointestinal, cardiovascular, respiratory and anti-diabetic therapies. Its continued investment in Actimed Therapeutics — targeting cancer cachexia and muscle-wasting conditions — signals a shift from a purely India-centric, price-led model toward a more innovation-linked one.
9. Biocon — India’s Biosimilars Specialist, New to the Top 10
Biocon is the newest entrant to this list, with a market cap of roughly ₹69,500 crore, up close to 30% year-on-year. It’s India’s only large-cap biosimilars specialist, holding a top-five global position in the category across 20+ biosimilars spanning insulins, monoclonal antibodies and oncology biologics. In FY26 its biosimilars business grew revenue 16% and EBITDA 40% on a like-for-like basis, positioned as a primary beneficiary of Budget 2026-27’s Biopharma Shakti programme.
10. Alkem Laboratories — Anti-Infectives, Generics, Growing Export Base
Alkem sells across 40+ countries through 19 manufacturing units and has filed 125+ ANDAs with the USFDA, with product coverage spanning anti-infectives, gastroenterology, dermatology, urology and OTC. All key manufacturing sites hold USFDA, UK MHRA, TGA (Australia) and WHO-GMP approvals — and Alkem was among the first wave of Indian companies to launch a branded generic semaglutide domestically in 2026.
Companies Worth Watching Just Outside the Top 10
Two names are close enough to the current top 10 that they’re worth tracking if you’re using this list for partner or plant benchmarking:
- Laurus Labs (~₹50,000–55,000 crore market cap) — the CDMO story of 2025-26, up over 80% in 2025 on a 50-million-vial oncology injectables plant and rising demand from global pharma diversifying supply chains away from China.
- Aurobindo Pharma — dropped out of the index top 10 by weightage but still exports to 150+ countries through 27 manufacturing and packing facilities, with FY2025 revenue of ₹31,724 crore and USFDA/UK MHRA approvals across its network.
FAQs — Top 10 Pharma Companies in India
Sun Pharmaceutical Industries holds the largest free-float market cap weightage in the Nifty Pharma Index as of June 2026, at roughly 23% — more than double the next-largest constituent, Divi’s Laboratories.
Yes. Biocon entered the top 10 in 2026 on strong biosimilars growth, displacing Aurobindo Pharma, while Dr. Reddy’s dropped from a historical top-five position following a weak Q4 FY26 driven by a stock-shelf write-down and export pricing pressure.
By free-float market capitalisation weightage within the NSE Nifty Pharma Index, which is NSE’s own semi-annually reviewed methodology for ranking the sector’s largest listed constituents. We cite the as-of date on every refresh because these figures move weekly.
Not directly — market cap reflects investor valuation, not plant capacity or GMP status. Most top-10 companies do hold multi-site USFDA and WHO-GMP approvals, which is a reasonable (though imperfect) proxy for manufacturing scale and compliance maturity.
Buy or Sell a Pharma Manufacturing Unit
If you’re evaluating capacity against the benchmarks these top 10 companies set — or considering a PCD franchise, plant purchase, or regulatory compliance consultation — Laafon Galaxy works directly with pharma manufacturing units across Haryana, Himachal Pradesh, Punjab, Uttar Pradesh and Uttarakhand. Check available units or call for a free consultation.
Sources: NSE Indices (Nifty Pharma Index factsheet and live weightage data, June 2026); company Q3/Q4 FY26 filings and press releases as reported by Univest, HDFC Sky, BusinessToday and PharmaNow; smart-investing.in NSE weightage tracker (June 19, 2026). This article is for industry-insight purposes only and is not investment advice.DATA VERIFIED AS OF: June 19, 2026 (NSE Nifty Pharma Index free-float weightage). Update this line each time you refresh the post.
